Waldencast获得Novaestiq和美国对Saypha gels的权利,并发展成为皮肤填充者。 Waldencast acquires Novaestiq and U.S. rights to Saypha® gels, expanding into dermal fillers.

Waldencast是一家全球美与健康公司, 已经获得Novaestiq公司和美国Sayphait 注射螺旋酸凝胶的权利, 将Obagi Medical的报价扩展到美国皮肤填充器市场。 Waldencast, a global beauty and wellness company, has acquired Novaestiq Corp. and the U.S. rights to Saypha® injectable hyaluronic acid gels, expanding Obagi Medical's offerings into the U.S. dermal filler market. Saypha目前正在寻求林业发展局的批准,以其安全和有效性著称。 Saypha® is currently seeking FDA approval and is known for its safety and effectiveness. 预计这一举动将大大扩大Waldencast的市场范围,将皮肤护理与Obagi医疗品牌下的美学治疗结合起来。 This move is expected to significantly grow Waldencast's market reach, combining skincare with aesthetic treatments under the Obagi Medical brand.